Sequential T cell response involved in tumor rejection of sarcoma, Meth A, in syngeneic mice

Japanese Journal of Cancer Research

Volumn 89, Issue 6, 1998, Pages 657-665

  Jiao, Yan ^a   Fujimoto, Shigeyoshi ^a  

^a KOCHI MEDICAL SCHOOL   (Japan)

Author keywords

CD4+ T cell clones; Meth A tumor rejection; T cell response

Indexed keywords

CD4 ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DELAYED HYPERSENSITIVITY; FEMALE; HELPER CELL; LYMPHOCYTE CLONE; LYMPHOKINE ACTIVATED KILLER CELL; MACROPHAGE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SARCOMA; SPLEEN CELL; T LYMPHOCYTE; TUMOR REJECTION;

EID: 0031848650     PISSN: 09105050     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.1998.tb03268.x     Document Type: Article

References (24)

1. Old, L. J., Boyse, E. A., Clarke, D. A. and Carswell, E. A. Antigenic properties of chemically induced tumors. Ann. N. Y. Acad. Sci., 101, 80-106 (1962).
2. DeLeo, A. B., Shiku, H., Takahashi, T., John, M. and Old L. J. Cell surface antigens of chemically induced sarcomas of the mouse I. Murine leukemia virus related antigens and alloantigens on cultured fibroblasts and sarcomas; description of a unique antigen on BALB/c Meth A sarcoma. J. Exp. Med., 146, 720-734 (1977).
3. Ting, C. C., Rodrigues, D. and Hong, J. X. Characterization of the responding populations for the generation of proliferative response to syngeneic Meth A tumor in BALB/c mice: requirement of T and B cell collaboration. J. Immunol., 125, 2742-2748 (1980).
4. Palladino, M. A., Jr., Srivastava, P. K., Oettgen, H. F. and DeLeo, A. B. Expression of a shared tumor-specific antigen by two chemically induced BALB/c sarcomas. Cancer Res., 47, 5074-5079 (1987).
5. DeLeo, A. B., Becker, M., Lu L. and Law, L. W. Properties of a Mr 110,000 tumor rejection antigen of the chemically induced BALB/c Meth A sarcoma. Cancer Res., 53, 1602-1607 (1993).
6. + T cells. Proc. Natl. Acad. Sci. USA, 91, 3171-3175 (1994).
7. + anti-Meth A cytotoxic T-lymphocytes: recognition of an epitope derived from the Meth A gp110 tumor rejection antigen. Cancer Res., 54, 4424-4429 (1994).
8. + cytotoxic T lymphocyte. Cancer Res., 55, 124-128 (1995).
9. Masuda, E. and Maeda, H. Changes in cellular components of spleen and lymph node cells and the effector cells responsible for Meth A tumor eradication induced by zinostatin stimalamer. Cancer Res., 56, 1868-1873 (1996).
10. Shimizu, M., Yamamoto, A., Nakano, H. and Matsuzawa, A. Augmentation of antitumor immunity with bacterial superantigen, staphylococcal enterotoxin B-bound tumor cells. Cancer Res., 56, 3731-3736 (1996).
11. + T cells. J. Immunol., 139, 3896-3901 (1987).
12. Chai J. G., Bando, T., Kobashi, S., Oka, M., Nagasawa, H., Nakai, S., Maeda, K., Himeno, K., Sato, M. and Ohkubo, S. An extract of seeds from Aeginetia indica L., a parasitic plant, induces potent antigen-specific antitumor immunity in Meth A-bearing BALB/c mice. Cancer Immunol. Immunother., 35, 181-185 (1992).
13. DuBois, G. C., Law, L. W. and Appella, E. Purification and biochemical properties of tumor-associated transplantation antigens from methylcholanthrene-induced murine sarcomas. Proc. Natl. Acad. Sci. USA, 79, 7669-7673 (1982).
14. + cytotoxic T-lymphocyte activation in mice. Cancer Res., 56, 5005-5011 (1996).
15. Fujimoto, S., Matsuzawa, T., Nakagawa, K. and Tada, T. Cellular interaction between cytotoxic and suppressor T cells against syngeneic tumors in the mouse. Cell. Immunol., 38, 378-387 (1978).
16. Hogan, M. M. and Vogel, S. N. Production of tumor necrosis factor by rIFN-gamma-primed C3H/HeJ (Lpsd) macrophages requires the presence of lipid A-associated proteins. J. Immunol., 141, 4196-4202 (1988).
17. Dubois, G. C, Appella, E., Law, L. W., DeLeo, A. B. and Old, L. J. Immunogenic properties of soluble cytosol fractions of Meth A sarcoma cells. Cancer Res., 40, 4204-4208 (1980).
18. Srivastava, P. K., DeLeo, A. B. and Old, L. J. Tumor rejection antigens of chemically induced sarcomas of inbred mice. Proc. Natl. Acad. Sci. USA, 83, 3407-3411 (1986).
19. + cytotoxic T-cells. Cancer Res., 53, 3257-3261 (1993).
20. Mayordomo, B. J., Loftus, D. J., Sakamoto, H., Cesare, C. M. D., Appasamy, P. M., Lotze, M. T., Storkus, W. J., Appella, E. and DeLeo, A. B. Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines. J. Exp. Med., 183, 1357-1365 (1996).
21. Mule, J. J., Krosnick, J. A. and Rosenberg, S. A. IL-4 regulation of murine lymphokine-activated killer activity in vitro. Effects on the IL-2-induced expansion, cytotoxicity. and phenotype of lymphokine-activated killer effectors. J. Immunol., 142, 726-733 (1989).
22. - precursor cell subsets. Int. Immunol., 3, 551-561 (1991).
23. Mosmann, T. R. and Coffman, R. L. Th1 and Th2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu. Rev. Immunol., 7, 145-173 (1989).
24. Mosmann, T. R. and Coffman, R. L. Heterogeneity of cytokine secretion patterns and functions of helper T cells. Adv. Immunol., 46, 111-147 (1989).